ClinicalTrials.gg
Active, not recruitingNCT05673785Updated Jun 12, 2026Results posted

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

A Phase 2 interventional study of Brentuximab Vedotin and Cyclophosphamide in Lymphoma, sponsored by Takeda. Active, not recruiting at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing Brentuximab Vedotin in Lymphoma — 1 open to participants now, 3 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma.

Enrollment
14th of 32
52 · median 51
Started
2023
the only one that year
Phase 2
12 of 32
none open now
Registered
31st of 32
by date
Lead sponsor
4 of 32
Takeda

Among the 32 studies testing Brentuximab Vedotin in Lymphoma, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 12 in phase 2, and was the 31st registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 32 studies testing Brentuximab Vedotin in Lymphoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing Brentuximab Vedotin in Lymphoma, or all of them as a file.
02

Study summary

This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL.

The main aims of the study are to evaluate:

  • Side effect from the A+CHP
  • Check how much A+CHP stays in their blood over time. This will help Takeda to work out the best dose to give people in the future.
  • If A+CHP improves outcome of newly diagnosed CD30+ PTCL

Brentuximab vedotin will be given through vein on Day 1 of each 21-day cycle. Cyclophosphamide and doxorubicin will be given through vein. Prednisone will be given orally daily on Days 1 through 5.

Read the detailed description

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat CD30+ PTCL in Chinese participants. This study will look at the efficacy, safety, and pharmacokinetics (PK) of A+CHP as frontline treatment for newly diagnosed CD30+ PTCL.

The study will enroll approximately 52 participants. Participants will be enrolled in a single group to receive:

  • Brentuximab vedotin 1.8 milligrams per kilogram (mg/kg) + Cyclophosphamide 750 milligrams per square meter (mg/m\^2), Doxorubicin 50 mg/m\^2 and Prednisone 100 mg

This multi-center trial will be conducted in China. The overall time to participate in this study is approximately 36 months.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have newly diagnosed CD30+ PTCL, per the Revised European American Lymphoma 2016 World Health Organization (WHO) classification, by local assessment. Tumor specimen must be submitted before enrollment for subsequent central pathology review to confirm histology (and anaplastic lymphoma kinase (ALK) status, if applicable), and CD30 expression. Eligible histologies include:

    1. ALK-positive systemic anaplastic large cell lymphoma (sALCL) with an International Prognostic Index (IPI) score of ≥2.
    2. ALK-negative sALCL.
    3. PTCL- not otherwise specified (NOS).
    4. Angioimmunoblastic T-cell lymphoma (AITL).
    5. Enteropathy associated T-cell lymphoma (EATL).
    6. Hepatosplenic T-cell lymphoma (HSTCL).
  2. (ECOG) performance status of less than or equal to 2.
  3. Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) imaging and with at least 1 bidimensionally measurable lesion (>1.5 cm in its largest dimension) by computed tomography (CT).
  4. Suitable venous access for the study-required blood sampling, including pharmacokinetic (PK) and immunogenicity sampling.
  5. Clinical laboratory values as specified below at screening/baseline within 7 days before the first dose of study drug:

    1. Total must be ≤1.5 times the (ULN) or ≤3 times the ULN for participants with Gilbert's disease or documented hepatic involvement with lymphoma.
    2. (ALT) and aspartate aminotransferase (AST) must be ≤3 times the ULN or ≤5 times the ULN for participants with an elevation that can be reasonably ascribed to the presence of disease in liver.
    3. Serum creatinine must be \<2.0 milligram per deciliter (mg/dL) and/or or calculated creatinine clearance >40 milliliter (mL)/minute.
    4. must be ≥8 grams per deciliter (g/dL). (Red blood cell transfusion is allowed ≥14 days before assessment.)
    5. >1.5×10\^9/liter (L).
    6. count ≥75×10\^9/L (unless documented bone marrow involvement with lymphoma).

Exclusion criteria

Exclusion Criteria:

  1. Systemic anticancer therapy, including traditional Chinese medicine with antitumor indication for disease under study before the first dose of study drugs.
  2. Major surgery within 28 days before the first dose of study drug.
  3. Known (HIV)-positive status.
  4. Known virus (HBV) surface antigen (HBsAg) seropositivity or active virus infection.

    Note: Participants who have positive HBV core antibody and are HBsAg negative can be enrolled, but must have an undetectable HBV viral load.

  5. Diagnosed or treated for another within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  6. Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug:

    1. Left-ventricular \<45%.
    2. Myocardial infarction within 6 months of enrollment.
    3. Class III or IV heart failure.
  7. Participants with current diagnosis of primary cutaneous CD30+ T-cell lymphoproliferative disorders and lymphomas. Participants with cutaneous anaplastic large cell lymphoma (ALCL) with extracutaneous tumor spread beyond locoregional lymph nodes are eligible (previous single-agent treatment to address cutaneous and locoregional disease is permissible).
  8. Participants with mycosis fungoides (MF) [including transformed MF].
  9. Uncontrolled diabetes mellitus.
  10. Baseline peripheral neuropathy ≥Grade 2 (National Cancer Institute [NCI CTCAE], version 5.0).
  11. History of progressive multifocal leukoencephalopathy (PML).
  12. Previous treatment with brentuximab vedotin or CD30 monoclonal antibody.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin + CHP

    Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2 IV, on Day 1 of each 21-day cycle, and prednisone 100 milligram (mg) tablets, orally, on Days 1 through Day 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurs first.

    Drug: Brentuximab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma

    ORR by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF assessment using the International Working Group (IWG) Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to approximately 7 months

  2. Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 30 days after the last dose of study treatment.

    Time frame: Up to approximately 7 months

  3. Number of Participants With Abnormal Changes From Baseline in Laboratory Measurements

    Laboratory parameters like Potassium, Aspartate Aminotransferase (AST), Bilirubin, Serum Gamma-glutamyl Transferase (GGT), High Glucose (Hyperglycemia), Neutrophils, Leukocytes, Platelets, and Hemoglobin were assessed. Intensity of changes in laboratory parameters were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to approximately 7 months

  4. Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)

    Time frame: Up to approximately 7 months

Secondary outcomes

  1. CR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma

    CR rate by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a CR by IRF assessment using the IWG Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease.

    Time frame: Up to approximately 7 months

  2. 1-Year Progression Free Survival (PFS) Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma

    The 1-year PFS rate by IRF assessment using the IWG Revised Response criteria is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

    Time frame: Month 12

  3. 1-Year Overall Survival (OS) Rate

    The 1-year OS rate is defined as the percentage of participants alive at 1 year. OS is defined as the time from the start of study treatment to the date of death due to any cause.

    Time frame: Month 12

  4. ORR by IRF Per 2014 Lugano Classification

    ORR by IRF per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to approximately 7 months

  5. ORR by Investigator Assessment Per 2014 Lugano Classification

    ORR by investigator assessment per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to approximately 7 months

  6. CR Rate by IRF Per 2014 Lugano Classification

    CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.

    Time frame: Up to approximately 7 months

  7. CR Rate by Investigator Assessment Per 2014 Lugano Classification

    CR rate by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses is defined as the percentage of participants who have achieved a CR by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease

    Time frame: Up to approximately 7 months

  8. Time to Response (TTR) by IRF Per 2014 Lugano Classification

    TTR by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by IRF following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to approximately 7 months

  9. Time to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification

    TTR by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by investigator assessment following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to approximately 7 months

  10. 1-Year PFS Rate by IRF Per 2014 Lugano Classification

    The 1-year PFS rate by IRF per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

    Time frame: Month 12

  11. 1-Year PFS Rate by Investigator Assessment Per 2014 Lugano Classification

    The 1-year PFS rate by investigator assessment per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

    Time frame: Month 12

  12. Duration of Response (DOR) by Investigator Assessment Per 2014 Lugano Classification

    DOR by investigator assessment using the 2014 Lugano Classification criteria is defined as the time between the first documentation of objective tumor response (CR or PR) by investigator assessment and the first subsequent documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

    Time frame: Up to approximately 36 months

  13. Serum Antibody-Drug Conjugate (ADC) Concentration

    Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug to selectively deliver treatment to cancer cells while minimizing damage to healthy cells.

    Time frame: Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days

  14. Plasma Monomethyl Auristatin E (MMAE) Concentration

    The plasma concentration of MMAE is a critical factor in determining the efficacy and safety of ADCs.

    Time frame: Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days

  15. Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive

    Time frame: Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.

  16. ADA Titer in Participants Positive for ADA Post Baseline

    Time frame: Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.

  17. Number of Participants With Negative and Positive Neutralizing Antibody Status (NAb)

    Time frame: Preinfusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days

07

Results

Posted Jun 12, 2026

Participant flow

Participants took part in the study at 14 investigative sites in China from 10 February 2023 to 27 April 2025. The study is ongoing.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin + CHP
Started52
Completed0
Not completed52
Withdrew: Death3
Withdrew: Lost to follow up1
Withdrew: Withdrawal by subject2
Withdrew: Ongoing46

Outcome measures

PrimaryOverall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma

ORR by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF assessment using the International Working Group (IWG) Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma
percentage of participantsBrentuximab Vedotin + CHP
Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma96.2 (86.8 to 99.5)
PrimaryPercentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 30 days after the last dose of study treatment.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsBrentuximab Vedotin + CHP
Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)100
PrimaryNumber of Participants With Abnormal Changes From Baseline in Laboratory Measurements

Laboratory parameters like Potassium, Aspartate Aminotransferase (AST), Bilirubin, Serum Gamma-glutamyl Transferase (GGT), High Glucose (Hyperglycemia), Neutrophils, Leukocytes, Platelets, and Hemoglobin were assessed. Intensity of changes in laboratory parameters were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Changes From Baseline in Laboratory Measurements
ParticipantsBrentuximab Vedotin + CHP
Postbaseline Shift From Grade 0 to Grade 4 Low Potassium1
Postbaseline Shift From Grade 0 to Grade 3 AST1
Postbaseline Shift From Grade 0 to Grade 3 Bilirubin1
Postbaseline Shift From Grade 0 to Grade 3 Serum GGT2
Postbaseline Shift From Grade 0 to Grade 3 High Glucose (Hyperglycemia),2
Postbaseline Shift From Grade 0 to Grade 3 Low Potassuium2
Postbaseline Serum Total Bilirubin >=2 ULN0
Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Neutrophil Count8
Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Leukocyte Count6
Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Platelet Count1
Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Leukocyte Count6
Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Neutrophil Count3
Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Platelet Count2
Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Hemoglobin1
Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Hemoglobin3
Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Leucocyte Count1
PrimaryNumber of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)
Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)
ParticipantsBrentuximab Vedotin + CHP
Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)1
SecondaryCR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma

CR rate by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a CR by IRF assessment using the IWG Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
CR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma
percentage of participantsBrentuximab Vedotin + CHP
CR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma75.0 (61.1 to 86.0)
Secondary1-Year Progression Free Survival (PFS) Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma

The 1-year PFS rate by IRF assessment using the IWG Revised Response criteria is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

Time frame:
Month 12

Results for this outcome have not been posted.

Secondary1-Year Overall Survival (OS) Rate

The 1-year OS rate is defined as the percentage of participants alive at 1 year. OS is defined as the time from the start of study treatment to the date of death due to any cause.

Time frame:
Month 12

Results for this outcome have not been posted.

SecondaryORR by IRF Per 2014 Lugano Classification

ORR by IRF per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
ORR by IRF Per 2014 Lugano Classification
percentage of participantsBrentuximab Vedotin + CHP
ORR by IRF Per 2014 Lugano Classification92.3 (81.5 to 97.9)
SecondaryORR by Investigator Assessment Per 2014 Lugano Classification

ORR by investigator assessment per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
ORR by Investigator Assessment Per 2014 Lugano Classification
percentage of participantsBrentuximab Vedotin + CHP
ORR by Investigator Assessment Per 2014 Lugano Classification94.2 (84.1 to 98.8)
SecondaryCR Rate by IRF Per 2014 Lugano Classification

CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
CR Rate by IRF Per 2014 Lugano Classification
percentage of participantsBrentuximab Vedotin + CHP
CR Rate by IRF Per 2014 Lugano Classification76.9 (63.2 to 87.5)
SecondaryCR Rate by Investigator Assessment Per 2014 Lugano Classification

CR rate by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses is defined as the percentage of participants who have achieved a CR by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease

Time frame:
Up to approximately 7 months
Reported as:
Number · percentage of participants
CR Rate by Investigator Assessment Per 2014 Lugano Classification
percentage of participantsBrentuximab Vedotin + CHP
CR Rate by Investigator Assessment Per 2014 Lugano Classification76.9 (63.2 to 87.5)
SecondaryTime to Response (TTR) by IRF Per 2014 Lugano Classification

TTR by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by IRF following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to approximately 7 months
Reported as:
Median · months
Time to Response (TTR) by IRF Per 2014 Lugano Classification
monthsBrentuximab Vedotin + CHP
Time to Response (TTR) by IRF Per 2014 Lugano Classification2.727 (2.694 to 2.760)
SecondaryTime to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification

TTR by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by investigator assessment following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to approximately 7 months
Reported as:
Median · months
Time to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification
monthsBrentuximab Vedotin + CHP
Time to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification2.727 (2.694 to 2.760)
Secondary1-Year PFS Rate by IRF Per 2014 Lugano Classification

The 1-year PFS rate by IRF per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

Time frame:
Month 12

Results for this outcome have not been posted.

Secondary1-Year PFS Rate by Investigator Assessment Per 2014 Lugano Classification

The 1-year PFS rate by investigator assessment per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

Time frame:
Month 12

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) by Investigator Assessment Per 2014 Lugano Classification

DOR by investigator assessment using the 2014 Lugano Classification criteria is defined as the time between the first documentation of objective tumor response (CR or PR) by investigator assessment and the first subsequent documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.

Time frame:
Up to approximately 36 months

Results for this outcome have not been posted.

SecondarySerum Antibody-Drug Conjugate (ADC) Concentration

Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug to selectively deliver treatment to cancer cells while minimizing damage to healthy cells.

Time frame:
Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days
Reported as:
Mean · nanograms per milliliter (ng/mL)
Serum Antibody-Drug Conjugate (ADC) Concentration
nanograms per milliliter (ng/mL)Brentuximab Vedotin + CHP
Cycle 1 - PredoseNA ± NA
Cycle 1 - End of infusion (30 min)32278.6310 ± 6782.22537
Cycle 1 - Day 3 (48 hr)8017.2624 ± 3262.42585
Cycle 1 - Day 5 (96 hr)4703.5579 ± 1795.74382
Cycle 2 - Predose364.0768 ± 151.95902
Cycle 2 - End of infusion (30 min)31953.2729 ± 8062.68391
Cycle 2 - Day 3 (48 hr)8944.7727 ± 3432.10921
Cycle 2 - Day 8 (168 hr)2674.7550 ± 626.08923
Cycle 3 - Predose558.8526 ± 181.81833
Cycle 4 - 15 to 21 Days Postdose1044.3557 ± 361.75958
Cycle 5 - Predose617.9578 ± 247.80106
Cycle 6 - Predose623.6881 ± 178.29961
Cycle 6 - 15 to 21 Days Postdose1052.5095 ± 412.67066
Cycle 7 - Predose660.0101 ± 198.78143
Cycle 8 - 15 to 21 Days Postdose1091.6060 ± 364.72862
Last - 15 to 21 Days Postdose1071.2758 ± 386.93255
SecondaryPlasma Monomethyl Auristatin E (MMAE) Concentration

The plasma concentration of MMAE is a critical factor in determining the efficacy and safety of ADCs.

Time frame:
Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days
Reported as:
Mean · picogram per milliliter (pg/mL)
Plasma Monomethyl Auristatin E (MMAE) Concentration
picogram per milliliter (pg/mL)Brentuximab Vedotin + CHP
Cycle 1 - Predose1070.00 ± NA
Cycle 1 - End of infusion (30 min)342.80 ± 430.172
Cycle 1 - Day 3 (48 hr)4038.50 ± 2251.734
Cycle 1 - Day 5 (96 hr)3664.39 ± 2682.503
Cycle 2 - Predose94.35 ± 83.847
Cycle 2 - End of infusion (30 min)211.03 ± 142.401
Cycle 2 - Day 3 (48 hr)1799.23 ± 502.966
Cycle 2 - Day 8 (168 hr)1481.65 ± 661.914
Cycle 3 - Predose91.21 ± 52.715
Cycle 4 - 15 to 21 Days Postdose294.93 ± 251.617
Cycle 5 - Predose107.18 ± 91.718
Cycle 6 - Predose103.79 ± 77.201
Cycle 6 - 15 to 21 Days Postdose329.65 ± 317.291
Cycle 7 - Predose118.26 ± 93.931
Cycle 8 - 15 to 21 Days Postdose241.97 ± 200.011
Last - 15 to 21 Days Postdose286.70 ± 267.333
SecondaryNumber of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive
Time frame:
Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.
Reported as:
Count of participants · Participants
Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive
ParticipantsBrentuximab Vedotin + CHP
Baseline Positive and Post-baseline Negative1
Baseline Negative and Post-baseline Negative51
Baseline Positive and Post-baseline Transiently Positive0
Baseline Negative and Post-baseline Transiently Positive0
Baseline Positive and Post-baseline Persistently Positive0
Baseline Negative and Post-baseline Persistently Positive0
SecondaryADA Titer in Participants Positive for ADA Post Baseline
Time frame:
Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Negative and Positive Neutralizing Antibody Status (NAb)
Time frame:
Preinfusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days
Reported as:
Count of participants · Participants
Number of Participants With Negative and Positive Neutralizing Antibody Status (NAb)
ParticipantsBrentuximab Vedotin + CHP
NAb Positive0
NAb Negative52

Adverse events

Collected over AEs including SAEs were recorded from signing the consent form up to 30 days after last dose of study treatment (approximately 7 months). Only Treatment-related SAEs were continued to be recorded during long-term follow up (up to a total of approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin + CHP3/52 (5.8%)18/52 (34.6%)52/52 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventBrentuximab Vedotin + CHP
PneumoniaInfections and infestations12/52
Febrile neutropeniaBlood and lymphatic system disorders3/52
Neutrophil count decreasedInvestigations3/52
White blood cell count decreasedInvestigations2/52
BacteraemiaInfections and infestations1/52
Gastrointestinal infectionInfections and infestations1/52
Haemophagocytic lymphohistiocytosisImmune system disorders1/52
Platelet count decreasedInvestigations1/52
Respiratory failureRespiratory, thoracic and mediastinal disorders1/52
Soft tissue infectionInfections and infestations1/52
Most frequent other events
Showing 10 of 58
Most frequent other events
EventBrentuximab Vedotin + CHP
White blood cell count decreasedInvestigations37/52
AnaemiaBlood and lymphatic system disorders35/52
Neutrophil count decreasedInvestigations35/52
Lymphocyte count decreasedInvestigations27/52
Alanine aminotransferase increasedInvestigations26/52
Aspartate aminotransferase increasedInvestigations22/52
Platelet count decreasedInvestigations21/52
NauseaGastrointestinal disorders18/52
VomitingGastrointestinal disorders18/52
HyperuricaemiaMetabolism and nutrition disorders16/52

Baseline characteristics

The Full Analysis Set (FAS) consisted of all enrolled participants.

Age, Continuous
Age, Continuous(years)Brentuximab Vedotin + CHP
Mean48.9 ± 15.49
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin + CHP
Female23
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brentuximab Vedotin + CHP
Hispanic or Latino0
Not Hispanic or Latino52
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin + CHP
American Indian or Alaska Native0
Asian52
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

16 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Apr 2025, 26 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 26 months is below that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 6, 2023
StartActual
Feb 10, 2023
Primary completionActual
Apr 27, 2025
CompletionEst.
Dec 31, 2027
Results first posted
Jun 12, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05673785
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Feb 10, 2023
Primary completion
Apr 27, 2025
Completion
Dec 31, 2027 (estimated)
Results posted
Jun 12, 2026
Last update
Jun 12, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Cyclophosphamide · Doxorubicin · Prednisone

Start the discussion